Want to see HK:2179 full AI Analyst Report?
Top Page
Jiangsu Recbio Technology Co., Ltd. Class H
(2179)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$4.00
▼(-4.31% Downside)
Action:Reiterated
Date:05/09/26
The score is primarily held back by weak financial performance—volatile revenue, persistent large losses, and ongoing negative operating/free cash flow—despite some improvement in leverage. Technicals add modest support with short-term bullish momentum (price above key short-term averages and positive MACD), but the move looks stretched and remains below the 200-day trend. Valuation is constrained by continued losses (negative P/E) and no dividend support.
Positive Factors
Vaccine and biologics focus
A core business centered on vaccines and innovative biologics aligns with durable structural demand for preventive medicines and public-health driven procurement. Long product development cycles and persistent global need can create recurring revenue streams and long product lifecycles once commercialized.
Negative Factors
Volatile, shrinking revenue
A sharp ~57% revenue decline in 2025 highlights weak commercialization traction and low revenue visibility. Persistent revenue volatility undermines unit economics and scale benefits, complicates planning for manufacturing capacity and R&D prioritization, and raises execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Vaccine and biologics focus
A core business centered on vaccines and innovative biologics aligns with durable structural demand for preventive medicines and public-health driven procurement. Long product development cycles and persistent global need can create recurring revenue streams and long product lifecycles once commercialized.
Read all positive factors
Jiangsu Recbio Technology Co., Ltd. Class H (2179) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.92B
Dividend YieldN/A
Average Volume (3M)18.23K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue GrowthN/A
EPS Growth2.44%
CountryHK
Employees531
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.15
Shares Outstanding458,092,160
10 Day Avg. Volume1,300
30 Day Avg. Volume18,233
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)2.70
Price to Sales (P/S)153.96
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.92
Revenue Forecast (FY)N/A
Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portio...
How the Company Makes Money
null...
Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.40M | 27.00M | 30.38M | 5.33M | 6.20M |
| Gross Profit | -91.46M | 15.95M | 22.34M | 5.33M | 6.20M |
| EBITDA | -486.44M | -523.97M | -569.87M | -847.67M | -590.00M |
| Net Income | -594.59M | -562.39M | -571.96M | -719.20M | -657.56M |
Balance Sheet | |||||
| Total Assets | 1.76B | 1.94B | 2.19B | 2.31B | 1.92B |
| Cash, Cash Equivalents and Short-Term Investments | 351.99M | 448.31M | 837.76M | 1.33B | 1.18B |
| Total Debt | 638.75M | 889.10M | 650.79M | 282.63M | 76.72M |
| Total Liabilities | 1.06B | 1.41B | 1.12B | 656.53M | 245.92M |
| Stockholders Equity | 706.14M | 529.32M | 1.07B | 1.66B | 1.67B |
Cash Flow | |||||
| Free Cash Flow | -601.50M | -636.66M | -862.18M | -888.04M | -710.79M |
| Operating Cash Flow | -502.64M | -464.82M | -638.07M | -579.54M | -472.92M |
| Investing Cash Flow | 35.43M | -279.04M | 9.42M | -378.43M | 68.70M |
| Financing Cash Flow | 499.77M | 218.06M | 275.27M | 839.44M | 1.23B |
Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis
Negative
4.18
Price Trends
4.95
Negative
4.75
Negative
5.46
Negative
Market Momentum
-0.06
Positive
43.81
Neutral
72.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Negative. The current price of 4.18 is below the 20-day moving average (MA) of 4.72, below the 50-day MA of 4.95, and below the 200-day MA of 5.46, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 43.81 is Neutral, neither overbought nor oversold. The STOCH value of 72.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2179.
Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$35.11B | 36.63 | 23.99% | ― | 16.65% | 0.87% | |
60 Neutral | HK$3.33B | 6.09 | 2.04% | ― | 1117.02% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$2.92B | -3.53 | -137.11% | ― | ― | 2.44% | |
45 Neutral | HK$2.53B | -21.10 | -14.78% | ― | -32.12% | -374.47% | |
41 Neutral | HK$34.22B | -52.03 | -10.78% | ― | 34.19% | 47.97% | |
40 Underperform | HK$2.10B | -8.75 | 11.40% | ― | -90.96% | 77.66% |
* Healthcare Sector Average
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.70
-3.26
-40.95%
HK:6998
Genor Biopharma Holdings Limited
1.66
-0.76
-31.40%
HK:1875
TOT BIOPHARM International Co. Ltd.
3.28
1.37
71.73%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
16.65
-4.10
-19.76%
HK:2197
Clover Biopharmaceuticals Ltd.
1.62
1.32
440.00%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
64.40
12.10
23.14%
Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events
Recbio Shareholders Approve All Resolutions at 2025 AGM
May 28, 2026
Jiangsu Recbio Technology Co., Ltd. reported that its 2025 annual general meeting in Taizhou, Jiangsu Province, achieved a quorum with shareholders and proxies representing about 51% of issued shares. All directors attended, and the meeting was co...
Jiangsu Recbio Boosts Hong Kong Free Float With Full H-Share Circulation
Apr 30, 2026
Jiangsu Recbio Technology has completed the full circulation of its H shares, converting 141,953,489 previously unlisted shares into H shares that began trading in Hong Kong on April 30, 2026. Following the conversion, the company’s share ca...
Jiangsu Recbio Sets 2025 AGM to Approve Accounts, Budget and Profit Plan
Apr 29, 2026
Jiangsu Recbio Technology Co., Ltd. has convened its 2025 annual general meeting for May 28, 2026 in Taizhou, Jiangsu Province, where shareholders will review the company’s 2025 financial accounts, annual report and board work report, as wel...
Jiangsu Recbio Advances Shingles and HPV Vaccines as 2025 Results Highlight Global Push
Mar 24, 2026
Jiangsu Recbio Technology reported audited annual results for 2025 alongside an update on its advancing vaccine pipeline, underscoring its positioning in high-value prophylactic markets. The company is progressing late-stage candidates targeting s...
Jiangsu Recbio Overhauls Key Governance Posts With New Joint Company Secretaries
Mar 24, 2026
Jiangsu Recbio Technology announced a reshuffle of key governance roles, with the resignation of company secretary, authorised representative and Hong Kong process agent Ms. Yung Mei Yee, effective 24 March 2026. The board noted that Ms. Yung has ...
Jiangsu Recbio Schedules March 2026 Board Meeting on 2025 Results and Dividend
Mar 12, 2026
Jiangsu Recbio Technology Co., Ltd., a PRC-incorporated joint stock company listed in Hong Kong, has a diversified board that includes executive, non-executive and independent non-executive directors, chaired by non-executive director Xu Haoyu. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.